- Home
- BTAI vs ACXP Comparison
BTAI vs ACXP Comparison
Compare BTAI & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- ACXP
- Stock Information
- Founded
- BTAI 2017
- ACXP 2017
- Country
- BTAI United States
- ACXP United States
- Employees
- BTAI N/A
- ACXP N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- ACXP Health Care
- Exchange
- BTAI Nasdaq
- ACXP Nasdaq
- Market Cap
- BTAI 8.3M
- ACXP 8.4M
- IPO Year
- BTAI 2018
- ACXP 2021
- Fundamental
- Price
- BTAI $1.93
- ACXP $0.49
- Analyst Decision
- BTAI Buy
- ACXP Strong Buy
- Analyst Count
- BTAI 5
- ACXP 2
- Target Price
- BTAI $34.60
- ACXP $10.00
- AVG Volume (30 Days)
- BTAI 289.2K
- ACXP 18.6M
- Earning Date
- BTAI 08-05-2025
- ACXP 08-08-2025
- Dividend Yield
- BTAI N/A
- ACXP N/A
- EPS Growth
- BTAI N/A
- ACXP N/A
- EPS
- BTAI N/A
- ACXP N/A
- Revenue
- BTAI $1,852,000.00
- ACXP N/A
- Revenue This Year
- BTAI $5.03
- ACXP N/A
- Revenue Next Year
- BTAI $291.01
- ACXP N/A
- P/E Ratio
- BTAI N/A
- ACXP N/A
- Revenue Growth
- BTAI 5.47
- ACXP N/A
- 52 Week Low
- BTAI $1.17
- ACXP $0.30
- 52 Week High
- BTAI $21.92
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- BTAI 56.97
- ACXP 51.70
- Support Level
- BTAI $1.69
- ACXP $0.46
- Resistance Level
- BTAI $2.08
- ACXP $0.56
- Average True Range (ATR)
- BTAI 0.20
- ACXP 0.10
- MACD
- BTAI 0.02
- ACXP -0.01
- Stochastic Oscillator
- BTAI 61.84
- ACXP 25.55
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.